GE HealthCare Technologies’ GEHC MIM Software recently announced the receipt of FDA clearance for performing Centiloid ...

Positron emission tomography (PET) beta-amyloid imaging is a vital tool in the diagnosis and treatment of Alzheimer’s disease. Fortunately, the Centers for Medicare and Medicaid Services (CMS ...

Researchers have shed new light on how amyloid-beta and tau proteins influence brain activity and cognitive decline in ...

GE HealthCare’s recently acquired MIM Software division has secured an FDA clearance for a tool to help quantify the density ...

A study published Wednesday in Nature Neuroscience sheds light into how amyloid-beta and tau proteins impact brain activity ...

A new study provides important insight into how amyloid-beta and tau proteins impact brain activity and possibly contribute to cognitive decline in Alzheimer's disease.

The GE HealthCare imaging tool is coming out as pharma companies release new therapies onto the market to help treat the ...

Researchers discover how amyloid-β and tau pathologies interact to drive early neurophysiological changes and cognitive ...

With FDA 510(k) clearance, MIMneuro may perform positron emission tomography-based imaging analysis of amyloid plaque, GE ...

Increasingly, researchers are looking to develop blood tests that could help make Alzheimer's diagnosis faster, more accurate ...

Patients with MS showed half the rate of amyloid pathology compared with people without MS, suggesting a possible protective ...